The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

MIT engineers have developed a tiny implantable device that could revolutionize emergency treatment for people with Type 1 diabetes. The device contains a powdered form of glucagon and can be remotely ...

Neal has more than 20 years of experience in financial and business journalism covering retail investing, airlines, pharmaceuticals, healthcare, sustainability, technology, and retail. He has worked ...

Troy Segal is an editor and writer. She has 20+ years of experience covering personal finance, wealth management, and business news. Toby Walters is a financial writer, investor, and lifelong learner.

This CaseCare360 activity reviews implantable drug delivery systems in DME, including identification of candidates for treatment, procedural strategies, and best practices for long-term monitoring.